Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (804)	4/17/1999 4:23:00 PM
From: scaram(o)uche	Respond to of 1073

Harry: >> it might be a viable treatment strategy for disorders where both features coexist, such as in PTSD and agitated depression << As far as I'm concerned, bingo! That's why I'm a shareholder. I believe that tricyclics, SRwhatevers, etc. just do not meet this need, and that the market will not only be defined but that it will also expand rapidly. Phase II is a long, long way from success, however. I feel that commentary regarding backup molecules is of interest for valuation, and I rarely feel that way. That is, I feel confident in the long-term potential for a research program in this area. Whether or not third-tier will survive to derive the benefits of all this potential is, of course, another issue..... and fodder for the bears. I have rarely seen a research program where the potential is so poorly understood/valued. However, your description is succinct and clear. Thanks! Rick

To: NeuroInvestment who wrote (804)	4/18/1999 12:15:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1073

BJ, NI, Rick,... Thanks. <<Janssen has completed three Phase I safety trials totalling 80 patients; there does not appear to be any sedation, abuse, or tolerance, the compound's blood brain barrier access is good.>> Any opinion why Jansenn choose first open label major depression PII tria? Are they still searching for optimal dose/schedules or some issue(s) on drug pharmacology are/were not yet clear? <<There has been increased interest in the field in the application of CRF modulation to Post-Traumatic Stress Disorder (PTSD), a disorder wherein anxiety is ubiquitous, and depression frequent. >> Does anyone (except J&J, pharma or bios) have CRFr antagonist candidate near or at early stage clinical trial for anxiety/depression? TIA Miljenko